Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Morten Schou"'
Autor:
Xenia Begun, Jawad H. Butt, Søren Lund Kristensen, Peter E. Weeke, Ole De Backer, Jarl E. Strange, Morten Schou, Lars Køber, Emil L. Fosbøl
Publikováno v:
American Heart Journal.
Autor:
Jesper Jensen, Massar Omar, Mulham Ali, Peter H. Frederiksen, Caroline Kistorp, Christian Tuxen, Camilla F. Andersen, Julie H. Larsen, Mads Kristian Ersbøll, Lars Køber, Finn Gustafsson, Jens Faber, Julie Lyng Forman, Jacob Eifer Møller, Morten Schou
Publikováno v:
Jensen, J, Omar, M, Ali, M, Frederiksen, P H, Kistorp, C, Tuxen, C, Andersen, C F, Larsen, J H, Ersbøll, M K, Køber, L, Gustafsson, F, Faber, J, Forman, J L, Møller, J E & Schou, M 2022, ' The effect of empagliflozin on contractile reserve in heart failure : Prespecified sub-study of a randomized, double-blind, and placebo-controlled trial ', American Heart Journal, vol. 250, pp. 57-65 . https://doi.org/10.1016/j.ahj.2022.04.008
Background: Sodium-glucose co-transporter-2 inhibitors improve cardiac structure but most studies suggest no change in left ventricular (LV) systolic function at rest. Whether sodium-glucose co-transporter-2 inhibitors improve LV contractile reserve
Autor:
Jon J Rasmussen, Jens Faber, Morten Schou, Louis Lind Plesner, Per Lav Madsen, Caroline Kistorp, Marie Lindhardt Johansen, Finn Gustafsson, Thomas Kümler, Tina Dreyer, Christian Selmer, Peter S. Ulriksen
Publikováno v:
American Heart Journal. 203:49-56
Illicit use of anabolic androgenic steroids (AAS) is associated with left ventricle (LV) systolic dysfunction and increased LV mass (LVM), but whether these findings persist in former AAS users has yet to be elucidated. The objective was to assess LV
Autor:
Lauge Østergaard, Lars Køber, Morten Schou, Morten Lamberts, Gunnar Gislason, Christian Torp-Pedersen, Emil L. Fosbøl, Rikke Sørensen, Kristian Kragholm, Jawad H. Butt, Matthew Phelps
Publikováno v:
American Heart Journal
Østergaard, L, Butt, J H, Kragholm, K, Schou, M, Phelps, M, Sørensen, R, Lamberts, M, Gislason, G, Torp-Pedersen, C, Køber, L & Fosbøl, E L 2021, ' Incidence of acute coronary syndrome during national lock-down : Insights from nationwide data during the Coronavirus disease 2019 (COVID-19) pandemic ', American Heart Journal, vol. 232, pp. 146-153 . https://doi.org/10.1016/j.ahj.2020.11.004
Østergaard, L, Butt, J H, Kragholm, K, Schou, M, Phelps, M, Sørensen, R, Lamberts, M, Gislason, G, Torp-Pedersen, C, Køber, L & Fosbøl, E L 2021, ' Incidence of acute coronary syndrome during national lock-down : Insights from nationwide data during the Coronavirus disease 2019 (COVID-19) pandemic ', American Heart Journal, vol. 232, pp. 146-153 . https://doi.org/10.1016/j.ahj.2020.11.004
Background Urgent recognition and treatment are needed in patients with acute coronary syndrome (ACS), however this may be difficult during the Coronavirus disease 2019 (COVID-19) pandemic with a national lock-down. We aimed to examine the incidence
Autor:
Kiomars Mahboubi, Jens Brønnum-Schou, Jacob E. Møller, Jawdat Abdulla, Christian Torp-Petersen, Henrik Wiggers, Gitte Nielsen, Anders Hostrup Larsen, Karen Kaae Dodt, Anne Sejr Knudsen, Søren Lund Kristensen, Jens Lomholdt, Christian Hassager, Helene Nørrelund, Dan Eik Høfsten, Vibeke Brogaard Hansen, Søren Vraa, Hans Eiskjær, Søren Mellemkjær, Lars Køber, Malene Hollingdal, Ilan Raymond, O.W. Nielsen, Kristine Serup-Hansen, Jens Christian Refsgaard, Kirsten Vilain Mikkelsen, Anders Barasa, Niels Eske Bruun, Hans Erik Bøtker, Bo Martin Bibby, Finn Gustafsson, Morten Schou, Morten Bøttcher, Gunnar Gislason, Bartlomiej Jonczy, Jette Sandberg Madsen, Flemming Hald Steffensen, Monica Petronela Poenaru, Karen Sillesen, Mikael Kjær Poulsen
Publikováno v:
American Heart Journal
Wiggers, H, Køber, L, Gislason, G, Schou, M, Poulsen, M K, Vraa, S, Nielsen, O W, Bruun, N E, Nørrelund, H, Hollingdal, M, Barasa, A, Bøttcher, M, Dodt, K, Hansen, V B, Nielsen, G, Knudsen, A S, Lomholdt, J, Mikkelsen, K V, Jonczy, B, Brønnum-Schou, J, Poenaru, M P, Abdulla, J, Raymond, I, Mahboubi, K, Sillesen, K, Serup-Hansen, K, Madsen, J S, Kristensen, S L, Larsen, A H, Bøtker, H E, Torp-Petersen, C, Eiskjær, H, Møller, J, Hassager, C, Steffensen, F H, Bibby, B M, Refsgaard, J, Høfsten, D E, Mellemkjær, S & Gustafsson, F 2021, ' The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART) : A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chronic heart failure and diabetes or prediabetes (Met-HeFT) ', American Heart Journal, vol. 231, pp. 137-146 . https://doi.org/10.1016/j.ahj.2020.09.020
Wiggers, H, Køber, L, Gislason, G, Schou, M, Poulsen, M K, Vraa, S, Nielsen, O W, Bruun, N E, Nørrelund, H, Hollingdal, M, Barasa, A, Bøttcher, M, Dodt, K, Hansen, V B, Nielsen, G, Knudsen, A S, Lomholdt, J, Mikkelsen, K V, Jonczy, B, Brønnum-Schou, J, Poenaru, M P, Abdulla, J, Raymond, I, Mahboubi, K, Sillesen, K, Serup-Hansen, K, Madsen, J S, Kristensen, S L, Larsen, A H, Bøtker, H E, Torp-Petersen, C, Eiskjær, H, Møller, J, Hassager, C, Steffensen, F H, Bibby, B M, Refsgaard, J, Høfsten, D E, Mellemkjær, S & Gustafsson, F 2021, ' The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART) : A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chronic heart failure and diabetes or prediabetes (Met-HeFT) ', American Heart Journal, vol. 231, pp. 137-146 . https://doi.org/10.1016/j.ahj.2020.09.020, https://doi.org/10.1016/j.ahj.2020.09.020
Wiggers, H, Køber, L, Gislason, G, Schou, M, Poulsen, M K, Vraa, S, Nielsen, O W, Bruun, N E, Nørrelund, H, Hollingdal, M, Barasa, A, Bøttcher, M, Dodt, K, Hansen, V B, Nielsen, G, Knudsen, A S, Lomholdt, J, Mikkelsen, K V, Jonczy, B, Brønnum-Schou, J, Poenaru, M P, Abdulla, J, Raymond, I, Mahboubi, K, Sillesen, K, Serup-Hansen, K, Madsen, J S, Kristensen, S L, Larsen, A H, Bøtker, H E, Torp-Petersen, C, Eiskjær, H, Møller, J, Hassager, C, Steffensen, F H, Bibby, B M, Refsgaard, J, Høfsten, D E, Mellemkjær, S & Gustafsson, F 2021, ' The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART) : A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chronic heart failure and diabetes or prediabetes (Met-HeFT) ', American Heart Journal, vol. 231, pp. 137-146 . https://doi.org/10.1016/j.ahj.2020.09.020
Wiggers, H, Køber, L, Gislason, G, Schou, M, Poulsen, M K, Vraa, S, Nielsen, O W, Bruun, N E, Nørrelund, H, Hollingdal, M, Barasa, A, Bøttcher, M, Dodt, K, Hansen, V B, Nielsen, G, Knudsen, A S, Lomholdt, J, Mikkelsen, K V, Jonczy, B, Brønnum-Schou, J, Poenaru, M P, Abdulla, J, Raymond, I, Mahboubi, K, Sillesen, K, Serup-Hansen, K, Madsen, J S, Kristensen, S L, Larsen, A H, Bøtker, H E, Torp-Petersen, C, Eiskjær, H, Møller, J, Hassager, C, Steffensen, F H, Bibby, B M, Refsgaard, J, Høfsten, D E, Mellemkjær, S & Gustafsson, F 2021, ' The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART) : A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chronic heart failure and diabetes or prediabetes (Met-HeFT) ', American Heart Journal, vol. 231, pp. 137-146 . https://doi.org/10.1016/j.ahj.2020.09.020, https://doi.org/10.1016/j.ahj.2020.09.020
OBJECTIVES: The DANHEART trial is a multicenter, randomized (1:1), parallel-group, double-blind, placebo-controlled study in chronic heart failure patients with reduced ejection fraction (HFrEF). This investigator driven study will include 1500 HFrEF
Autor:
Finn Gustafsson, Andreas Kjaer, Pernille Corell, Per Hildebrandt, Caroline Kistorp, Morten Schou
Publikováno v:
American heart journal. 154(1)
Background N-terminal pro–brain natriuretic peptide (NT-proBNP) carries prognostic information in patients with chronic heart failure and predicts risk for mortality and cardiovascular events. It is unknown whether NT-proBNP predicts risk for hospi